Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

NYSE:AMRX   4:00:00 PM EDT
2.41
+0.04 (+1.69%)
Other Pre-Announcement

Amneal Reports Q3 Net Revenue Of $546 Mln

Published: 11/04/2022 10:15 GMT
Amneal Pharmaceuticals Inc - Ordinary Shares - Class A (AMRX) - Amneal Reports Third Quarter 2022 Financial Results.
Maintaining 2022 Full Year Outlook.
Q3 2022 Net Revenue of $546 Million.
Qtrly Diluted Loss per Share of $0.02.
Qtrly Adjusted Diluted Earnings per Share (non-GAAP) $0.14.
Q3 Earnings per Share View $0.18, Revenue View $561.9 Million -- Refinitiv Ibes Data (analyst estimates).
FY2022 Earnings per Share View $0.68, Revenue View $2.20 Billion -- Refinitiv Ibes Data (analyst estimates).